Medtech industry's uptake of 3-D printing catches eye of US FDA
This article was originally published in SRA
The US Food and Drug Administration is to explore whether it will need to develop guidelines and standards to cover the fast-growing medical device manufacturing technique of additive manufacturing, often referred to as 3–D printing1.
You may also be interested in...
Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.
New medicines under evaluation at the European Medicines Agency.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).